M&G is an investment manager whose Catalyst strategy focuses on innovative private assets tackling environmental and social challenges.
The Cambridge biotechnology company has raised £31.4m from investors including M&G and Amadeus Capital Partners to advance its desktop protein printer.
"There’s a fundamental productivity problem in biotech today. A biotech scientist needs to know how to make proteins to design drugs. That’s like expecting a computer scientist to know how to build a computer to design software,"
M&G Investments contributed £35m to the £195m private transaction alongside Temasek, Wellington Management, and Nikon.
"The technology developed by Oxford Nanopore is being used in a broad range of scientific research applications, including to further biomedical science, to characterise pathogens in microbiology and public health. This is an example of how institutional investors can play an important role in accelerating growth in companies that provide a wider benefit to society."
